Efficacy of teplizumab for treatment of type 1 diabetes: A meta‐analysis of randomized controlled trials

• Published in: Diabetes/metabolism research and reviews 2024-05, Vol.40 (4), p.e3806-n/a
• Main Authors: Heidari, Ehsan, Shafiee, Arman, Noorian, Shahab, Rafiei, Mohammad Ali, Abbasi, Mohammad, Amini, Mohammad Javad, Safari, Omid, Aghamahdi, Fatemeh, Bakhtiyari, Mahmood
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Antibodies, Monoclonal, Humanized - therapeutic use; Child; Clinical trials; Diabetes; Diabetes mellitus (insulin dependent); Diabetes Mellitus, Type 1 - drug therapy; Glycated Hemoglobin - analysis; Humans; Hypoglycemic Agents - therapeutic use; Immunomodulation; Insulin; Insulin - therapeutic use; Meta-analysis; Monoclonal antibodies; Patients; Peptides; Prognosis; Quality control; Randomized Controlled Trials as Topic; teplizumab; treatment; Treatment Outcome; type 1 diabetes; Young Adult
• ISSN: 1520-7552; 1520-7560
• DOI: 10.1002/dmrr.3806

Background The management of Type 1 Diabetes Mellitus (T1DM) is a significant clinical challenge. This study evaluated the efficacy of teplizumab, an immunomodulatory drug, in patients with T1DM, using a systematic review and meta‐analysis approach. Methods We systematically searched multiple databases including Medline, Scopus, and others up to 10 January 2024, without language or regional restrictions. We included randomized controlled trials (RCTs) comparing teplizumab with placebo in T1DM patients. Results Our analysis incorporated 8 RCTs, predominantly involving participants aged 7–35 years, diagnosed with T1DM and treated with 14‐day courses of teplizumab. The primary outcomes included insulin use, C‐peptide levels, and HbA1c levels. We observed a significant reduction in insulin use in the teplizumab group standardised mean difference of −0.50 (95% Confidence Interval [CI]: −0.76 to −0.23, p